CytomX Therapeutics (CTMX) Set to Announce Earnings on Thursday

CytomX Therapeutics (NASDAQ:CTMX - Get Free Report) will be posting its quarterly earnings results after the market closes on Thursday, November 7th. Analysts expect CytomX Therapeutics to post earnings of ($0.16) per share for the quarter.

CytomX Therapeutics (NASDAQ:CTMX - Get Free Report) last announced its earnings results on Thursday, August 8th. The biotechnology company reported ($0.08) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.01). The business had revenue of $25.12 million for the quarter, compared to the consensus estimate of $21.79 million. CytomX Therapeutics had a net margin of 9.27% and a negative return on equity of 27.44%. During the same quarter in the previous year, the company earned ($0.02) EPS. On average, analysts expect CytomX Therapeutics to post $0 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

CytomX Therapeutics Stock Up 5.5 %

NASDAQ CTMX traded up $0.05 during trading on Friday, hitting $1.05. The company's stock had a trading volume of 1,447,111 shares, compared to its average volume of 2,588,192. The firm has a market cap of $82.02 million, a P/E ratio of 7.50 and a beta of 1.04. The firm has a 50 day moving average price of $1.16 and a 200 day moving average price of $1.50. CytomX Therapeutics has a 52 week low of $0.99 and a 52 week high of $5.85.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a "neutral" rating on shares of CytomX Therapeutics in a research report on Friday, September 13th. Four research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Hold" and an average target price of $5.77.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.